Attention Deficit Disorder With Hyperactivity Clinical Trial
Official title:
Methylphenidate Treatment for Cocaine Abuse and ADHD
Many cocaine dependent individuals are also diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Methylphenidate (Ritalin) is currently approved to treat individuals diagnosed with ADHD. The purpose of this study is to determine the effectiveness of methylphenidate in treating ADHD symptoms in cocaine dependent individuals.
Methylphenidate (MPH) is commonly used to treat individuals diagnosed with ADHD. The purpose
of this study is to determine the effectiveness of MPH in treating adult cocaine dependent
individuals who are also diagnosed with ADHD.
Participants in this 14-week, double-blind, placebo-controlled study will be randomly
assigned to receive either sustained-release MPH or placebo. All participants will receive
individual cognitive behavioral therapy. The trial will last 14 weeks. It will include a
1-week placebo lead-in phase and a 2-week dose titration phase, followed by 11 weeks on a
stable dose of MPH. During the titration phase, MPH will be given twice a day, starting at a
dose of 10 mg/day. The dose will increase by 10 mg each day, until a final stable dose of 40
mg/day is reached. At this time, sustained-release MPH will be given as two 20 mg doses (one
in the morning and one in the afternoon). Depending on a participant's tolerance of MPH, the
dose will be increased to a maximum of 60 mg/day (40 mg in the morning and 20 mg in the
afternoon). Participants who are unable to tolerate a dose of at least 40 mg/day of MPH will
be discontinued from the study. Assessments of ADHD symptoms will be completed at weekly
study visits. In addition, drug use assessments will also be completed and will include
self-reports and urine toxicology tests.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00202605 -
Safety and Efficacy of SPD465 in Adults With ADHD
|
Phase 2 | |
| Not yet recruiting |
NCT02677519 -
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
|
Phase 4 | |
| Completed |
NCT02730572 -
Concerta (Methylphenidate) -To-Generic Switch Study
|
N/A | |
| Completed |
NCT01681082 -
Psychological Effects of Tai Chi Training
|
N/A | |
| Active, not recruiting |
NCT01330693 -
Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy
|
Phase 3 | |
| Completed |
NCT00830700 -
Children's Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study
|
N/A | |
| Completed |
NCT00626236 -
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
|
Phase 2 | |
| Completed |
NCT01012622 -
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
|
Phase 4 | |
| Completed |
NCT00598182 -
Adherence and Long-term Effect of OROS Methylphenidate (CONCERTA): A Follow-up Study
|
N/A | |
| Completed |
NCT00381407 -
Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder
|
N/A | |
| Completed |
NCT00178503 -
Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
|
Phase 2/Phase 3 | |
| Completed |
NCT00247572 -
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories
|
Phase 2 | |
| Completed |
NCT00557011 -
NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD
|
Phase 2 | |
| Completed |
NCT00218322 -
Effectiveness of ATMX in Treating Adolescents With ADHD and SUD
|
Phase 4 | |
| Completed |
NCT00118911 -
Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder
|
N/A | |
| Completed |
NCT00071656 -
Psychosocial Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Type I
|
N/A | |
| Active, not recruiting |
NCT00057668 -
Preventing Behavior Problems in Children With ADHD
|
Phase 2 | |
| Completed |
NCT00050050 -
Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder
|
Phase 1 | |
| Completed |
NCT00050622 -
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
|
N/A | |
| Completed |
NCT00031395 -
Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children
|
Phase 3 |